Exchange: NASDAQ·Updated 07:53 PM EST

COGT News

News
all
press releases
Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recomm...
MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recomm...
MarketBeat
More News
Cogent Biosciences, Inc. (COGT) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
Cogent Biosciences (NASDAQ:COGT) Sets New 12-Month Low - Should You Sell...
MarketBeat
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 14.59% on an annualized basis producing an average annual return of 26.37%. Currently, Cogent Biosciences has a market capitalizationread more...
Benzinga
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a market capitalizationread more...
Benzinga
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 18.64% on an annualized basis producing an average annual return of 30.55%. Currently, Cogent Biosciences has a market capitalizationread more...
Benzinga
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 22.44% on an annualized basis producing an average annual return of 33.55%. Currently, Cogent Biosciences has a market capitalizationread more...
Benzinga
Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 28.96% on an annualized basis producing an average annual return of 40.76%. Currently, Cogent Biosciences has a market capitalizationread more...
Benzinga
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now...
Yahoo! Finance: News

Advertisement|Remove ads.